Also, U.S. average hourly earnings rose +0.5% m/m and +4.1% y/y in January, stronger than expectations of ... weaker than expectations of 49.7. U.S. Steel (X) rose over +8% in pre-market trading after ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oric Pharmaceuticals (ORIC – Research ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

The S&P 500 Index ($SPX) (SPY) today is up +0.73%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.27%, and the Nasdaq ...

Vertex Securities Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 36.49 Crore) operating in Financial Services sector. Vertex Securities Ltd. key ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Ivy Rose Ct: Grotto Investments LLC to Fischer Single Family Homes Iv LLC; $120,000 9408 Glenwood Ct: Castle Alexandra & ...

Pre-Market: 8:48:49 a.m. EST ...